Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) reported $70.87 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 35.2%. EPS of -$0.13 for the same period compares to -$0.20 a year ago.The reported revenue represents a surprise of +14.61% over the Zacks Consensus Estimate of $61.84 million. With the consensus EPS estimate being -$0.16, the EPS surprise was +16.13%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:ClonoSEQ test volume: 32,595 versus the three-analyst average estimate of 31,235.Revenue- Total Immune Medicine: $3.78 million versus the three-analyst average estimate of $6.23 million. The reported number represents a year-over-year change of -56.7%.Revenue- Total MRD: $67.09 million compared to the $55.23 million average estimate based on three analysts. The reported number represents a change of +53.5% year over year.Revenue- MRD revenue- Service: $58.09 million versus the three-analyst average estimate of $55.23 million.Revenue- Immune Medicine revenue- Service and licensing revenue: $3.78 million compared to the $6.54 million average estimate based on two analysts. The reported number represents a change of -26.2% year over year.View all Key Company Metrics for Adaptive Biotechnologies here>>>Shares of Adaptive Biotechnologies have returned +3% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks